Prevention of venous thromboembolism in elderly patients

doi:10.16352/j.issn.1001-6325.2024.07.0916

Abstract

Abstract: Venous thromboembolism (VTE) is a common disease with high morbidity and mortality. The incidence and mortality of VTE are higher in elderly patients and increased level of D-dimer, a thrombosis marker is positively related with age. Therefore, the diagnostic threshold needs to be adjusted to screen VTE with D-dimer level. Elderly patients may still have VTE after implementation of anticoagulant prevention, and increasing age is a high risk factor for bleeding after anticoagulant prevention. Whether elderly patients need to be monitored for anticoagulant prevention of VTE, and the relationship between age and VTE recurrence remains to be determined. In-depth research on the prevention of VTE in elderly patients and exploration of innovative VTE prevention strategies may orient future research.

Key words: elderly patient, venous thromboembolism, prevention

CLC Number:

R543.6

DING Mengxi, WANG Chunmei. Prevention of venous thromboembolism in elderly patients[J]. Basic & Clinical Medicine, 2024, 44(7): 916-920.

References

[1]Zhang X, Cai Q, Wang X, et al. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)[J]. J Thromb Thrombolysis, 2021,52:863-871.
[2]Nicholson M, Chan N, Bhagirath V, et al. Prevention of venous thromboembolism in 2020 and beyond[J]. J Clin Med, 2020,9.doi: 10.3390/jcm9082467.
[3]Debnath J, Sharma V. Diagnosing pulmonary thromboembolism: concerns and controversies[J]. Med J Armed Forces India,2022,78:17-23.
[4]Zhang Z, Lei J, Shao X, et al. Trends in hospitalization and in-hospital mortality from VTE, 2007 to 2016, in China[J]. Chest, 2019,155:342-353.
[5]Khan F, Tritschler T, Kahn S R, et al. Venous thromboembolism[J]. The Lancet, 2021,398:64-77.
[6]Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline[J]. Chest, 2022,162:e207-e243.
[7]熊雪, 李海磊, 舒春花, 等. 静脉血栓栓塞症风险评估工具的研究进展[J]. 中国当代医药, 2023,30:28-31.
[8]Chen X, Huang J, Liu J, et al. Venous thromboembolism risk factors and prophylaxis of elderly intensive care unit patients in a Chinese general hospital[J]. Ann Palliat Med, 2021,10:4453-4462.
[9]Lavon O, Tamir T. Evaluation of the padua prediction score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records[J]. Sci Rep, 2022,12:6121.doi:10.1038/s41598-022-10209-9.
[10]Tritschler T, Aujesky D. Venous thromboembolism in the elderly: a narrative review[J]. Thromb Res, 2017,155:140-147.
[11]中国老年医学学会周围血管疾病管理分会, 赵纪春, 黄建华, 等. 老年人静脉血栓栓塞症防治中国专家共识[J]. 中国普外基础与临床杂志, 2023,30:1173-1187.
[12]中国老年医学学会重症医学分会, 浙江省重症医学临床医学研究中心. 老年重症患者静脉血栓栓塞症预防中国专家共识(2023)[J]. 中华危重病急救医学, 2023,35:561-572.
[13]Tritschler T, Kraaijpoel N, Le Gal G, et al. Venous thromboembolism: advances in diagnosis and treatment[J]. JAMA, 2018,320:1583-1594.
[14]De Pooter N, Brionne-François M, Smahi M, et al. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: clinical performance and cost-effectiveness analysis[J]. J Thromb Haemost, 2021,19:1271-1282.
[15]Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for manage-ment of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients[J]. Blood Adv, 2018,2:3198-3225.
[16]李文欣, 李兴升. 老年患者抗凝药物使用进展[J]. 临床医学进展, 2021,11:5911-5916.
[17]Wang CM, Guo XF, Liu LM, et al. Prevention of deep vein thrombosis by panax notoginseng saponins combined with low-molecular-weight heparin in surgical patients[J]. Chin J Integr Med, 2022,28:771-778.
[18]傅日斌, 郑欣鹏, 林劲松, 等. 利伐沙班和低分子肝素在老年粗隆间骨折患者围手术期的应用效果分析[J]. 中国医药, 2024,19:93-96.
[19]Palareti G, Poli D. The prevention of venous thromboembolism recurrence in the elderly: a still open issue[J]. Expert Rev Hematol, 2018,11:903-909.
[20]Wang C, Ning YC, Song LP, et al. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial[J]. BMJ Open, 2023,13:e69742.doi:10.1136/bmjopen-2022-069742.
[21]徐晓艳, 郭慧玲, 周伟明, 等. 静脉血栓栓塞复发危险因素分析及护理[J]. 血栓与止血学, 2020,26:679-682.